KRMD Earnings

KRMD reported its earnings on 2026-03-12, showcasing a revenue of 10.89M against an estimate of 10.89M, resulting in a 0.05% surprise. The EPS was -0.01, surpassing the expected -0.02 by 50%. The stock experienced a -0.7% price change on the earnings day and a 0.93% change over the next five days, reflecting market reactions to the results.

Following KRMD's earnings announcement on 2026-03-12, the stock price moved by -0.7% on the day of the release. Over the subsequent five days, it saw a 0.93% change. Historically, KRMD's stock price tends to shift by an average of 5.38% in the 10 days leading up to earnings and 7.68% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate KRMD's annual revenue to reach 11.18M, while the EPS is projected at -0.01. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between KRMD's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, KRMD's stock price typically moves by 5.38% in the 10 days before its earnings and 7.68% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.01 and revenue of 11.18M.

The earnings call reveals strong financial performance with a 23% YoY revenue growth and international expansion. The company raised its revenue guidance, maintained positive cash flow, and achieved positive adjusted EBITDA. Despite slight margin decreases, the strategic focus on expanding market share and new product launches is promising. The Q&A highlights further growth potential in international markets and new drug approvals. The overall sentiment is positive, with expectations of continued growth driven by strategic initiatives and market expansion, suggesting a likely positive stock price movement.